Study finds link between osteoporosis and osteoporosis treatment and a reduced risk of breast cancer recurrence

New research, presented by the NCIC Clinical Trials Group (CTG) at the American Society of Clinical Oncology (ASCO) meeting in Chicago, draws a significant link between the development of osteoporosis, osteoporosis treatment and a reduced risk of breast cancer recurrence. The study involved almost 1,300 postmenopausal women with a diagnosis of early breast cancer who used AIs and who had osteoporosis. The researchers found that the women with osteoporosis experienced improved event-free survival (how effective a treatment is at preventing recurrence) and distant disease-free survival (a measure of how long patients remain free of metastasis at distant sites), pointing to the need to weigh the risks and benefits of treatment with AIs. Read the news article here.